XEN D0501

Drug Profile

XEN D0501

Alternative Names: BAY-69-9426; XEN-D0501

Latest Information Update: 27 Jan 2016

Price : $50

At a glance

  • Originator Xention
  • Developer Ario Pharma; Provesica
  • Class Small molecules; Urologics
  • Mechanism of Action TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cough
  • No development reported Overactive bladder

Most Recent Events

  • 27 Jan 2016 XEN D0501 is available for licensing as of 27 Jan 2016. http://www.ariopharma.com
  • 08 Sep 2015 No recent reports on development identified - Phase-II for Overactive bladder in Belgium, Estonia, Romania, Russia and United Kingdom (PO)
  • 01 May 2015 Xention and Ario Pharma complete a phase II trial in Cough in United Kingdom (NCT02233699)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top